Detalles de la búsqueda
1.
A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.
Cell
; 183(2): 347-362.e24, 2020 10 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33064988
2.
A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma.
Br J Cancer
; 124(4): 744-753, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33311588
3.
Gene expression analysis in biomarker research and early drug development using function tested reverse transcription quantitative real-time PCR assays.
Methods
; 59(1): 10-9, 2013 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-22796720
4.
Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer.
Cancer Cell
; 40(9): 1010-1026.e11, 2022 09 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36027916
5.
A dose escalation study of RO6870810/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndrome.
Leuk Lymphoma
; 62(7): 1740-1748, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33586590
6.
Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma.
Blood Adv
; 5(22): 4762-4770, 2021 11 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-34581757
7.
A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma.
Blood Cancer J
; 11(9): 149, 2021 09 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34480019
8.
Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors.
Clin Cancer Res
; 22(4): 858-67, 2016 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26446946
9.
Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors.
J Clin Oncol
; 22(16): 3366-74, 2004 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-15310782
10.
A phase I clinical and pharmacokinetic study of Ro 31-7453 given as a 7- or 14-day oral twice daily schedule every 4 weeks in patients with solid tumors.
Clin Cancer Res
; 10(13): 4374-82, 2004 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-15240525
11.
A phase I monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers.
Clin Cancer Res
; 21(2): 258-66, 2015 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25388164
12.
A phase I trial of pharmacokinetic modulation of carboxyamidotriazole (CAI) with ketoconazole in patients with advanced cancer.
Cancer Chemother Pharmacol
; 54(5): 377-84, 2004 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-15235824
13.
RG7212 anti-TWEAK mAb inhibits tumor growth through inhibition of tumor cell proliferation and survival signaling and by enhancing the host antitumor immune response.
Clin Cancer Res
; 19(20): 5686-98, 2013 Oct 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23974006
14.
Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors.
J Clin Oncol
; 30(19): 2348-53, 2012 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22529266
15.
Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients.
Mol Cancer Ther
; 8(9): 2517-25, 2009 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-19755512
Resultados
1 -
15
de 15
1
Próxima >
>>